There is a statement going around among orthopaedists and rheumatologists that the weather changes could trigger joint pain. But it is actually the patients who visit them, who convey this myth. Is there any truth behind it?
NiV was first discovered in Malaysia and Singapore in 1998-1999 where around 250 infected cases and 100 deaths were reported. Between 2001 and 2004, NiV caused a deadly outbreak in Bangladesh followed by the West Bengal state in India.
EHR vendor Allscripts has made an agreement to purchase patient communication app maker Health Grid for $60 million in cash, with an additional $50 million in earnout payments based on Health Grid achieving certain revenue targets over the next three years, according to a recently registered SEC filing. The merger of the two companies is expected to close sometime during Q2 2018.
A Fitbit official disclosed eight mobile health apps, including two focused on diabetes management and one on oncology care.
During the Fitbit Q1 earnings call, the company confirmed its focus on digital health regardless of the expected decline in sales numbers. Currently, Fitbit is focusing on its new alliance with Google, wherein the two companies will work together to speed up innovation in the digital health space to provide clear EHRs and precise patient data to help the clinicians.
Suki, a startup that makes an AI-powered and voice-enabled digital assistant for doctors, has just landed $20 million in a funding round led by Venrock, with participation from First Round, Social Capital, and Marc Benioff.
The Food and Drug Administration plans to launch a full-scale version of its digital health precertification program by the end of the year.
In clinical studies, more than half of patients receiving risankizumab achieved complete skin clearance (PASI 100) at one year (52 weeks) (1) The Biologics License Application is supported by four Phase 3 studies of more than 2,000 patients with moderate to severe plaque psoriasis (1-3) Risankizumab is an investigational compound designed to selectively inhibit IL-23 by binding to its p19 subunit and is being evaluated for the potential to deliver long-term skin clearance for psoriasis patients with 12-week dosing (4)
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that Celgene Corporation has exercised its right to expand its collaboration agreement for the research, development, and commercialization of bispecific antibody therapeutics using Zymeworks’ Azymetric™ platform.
GSK is shifting resources towards key therapeutic classes, including respiratory disease.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.